Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
NicOx S.A.
NXOACurrent price
0.13 EUR
+0.011 EUR (+9.91%)
Last closed
0.15 EUR
Company
–
ISIN
unknown
Sector
Healthcare
Industry
Biotechnology
Exchange
Stuttgart Exchange
Capitalization
9 725 783 EUR
Yield for 12 month
-62.32 %
1Y
3Y
5Y
10Y
15Y
NXOA
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. Nicox S.A. is developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular related associated with allergic conjunctivitis. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France. Address: Sundesk Sophia Antipolis, Valbonne, France, 06410
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
0.9 EURP/E ratio
–Dividend Yield
–Current Year
+255 716 EUR
Last Year
+210 941 EUR
Current Quarter
+1 724 342 EUR
Last Quarter
+1 831 803 EUR
Current Year
-11 445 534 EUR
Last Year
+23 439 315 EUR
Current Quarter
–
Last Quarter
–
Key Figures NXOA
1 year
3 years
5 years
10 years
EBITDA
-18 927 966 EUR
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-13.26 %
PEG Ratio
–
Return On Equity TTM
-32.68 %
Wall Street Target Price
0.9 EUR
Revenue TTM
3 556 145 EUR
Book Value
0.9 EUR
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
21.2 %
Dividend Yield
–
Gross Profit TTM
-14 647 457 EUR
Earnings per share
-0.42 EUR
Diluted Eps TTM
-0.42 EUR
Most Recent Quarter
II 2023
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics NXOA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History NXOA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:5
Payout Ratio
–
Last Split Date
03.12.2015
Dividend Date
–
Stock Valuation NXOA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
3.6544
Price Sales TTM
2.7349
Enterprise Value EBITDA
-1.8263
Price Book MRQ
0.4854
Financials NXOA
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators NXOA
For 52 weeks
0.15 EUR
0.49 EUR
50 Day MA
0.18 EUR
Shares Short Prior Month
–
200 Day MA
0.33 EUR
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart